Aclaris Therapeutics - ACRS Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings or view top-rated stocks.

4 analysts have issued 1-year price targets for Aclaris Therapeutics' stock. Their ACRS share price forecasts range from $26.00 to $50.00. On average, they expect the company's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 176.4% from the stock's current price.
View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts.

Aclaris Therapeutics' stock was trading at $14.54 at the start of the year. Since then, ACRS stock has decreased by 5.4% and is now trading at $13.75.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our ACRS earnings forecast.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its quarterly earnings data on Wednesday, August, 3rd. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.05. The biotechnology company earned $1.53 million during the quarter, compared to analyst estimates of $1.59 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 40.14% and a negative net margin of 1,355.98%.

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Commodore Capital LP (3.62%), Point72 Asset Management L.P. (2.60%), Renaissance Technologies LLC (1.99%), FMR LLC (1.86%), State Street Corp (1.85%) and Deutsche Bank AG (1.76%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends.

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACRS stock can currently be purchased for approximately $13.75.

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $916.74 million and generates $6.76 million in revenue each year. The biotechnology company earns $-90,860,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.